Carmen Chang
CIK 1746342 · last filed 2026-06-15
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$659.03M
Companies
15
Total Filings
42
Lifetime Open-Market Net
$175.26M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| COUR | Director | 2,328,403 | $5.85 | $13.62M | -$14.5K | 8 | 2026-06-15 |
| KRRO | 10%+ Owner | 1,297,893 | $10.50 | $13.63M | $3.30M | 2 | 2026-03-12 |
| SGP | 10%+ Owner | 6,035,038 | $21.62 | $130.48M | $15.00M | 1 | 2026-02-11 |
| NeueHealth, Inc. (BHG) Delisted | Director | 1,160,234 | $16.35 | $18.97M | $34.97M | 8 | 2025-10-06 |
| NeueHealth, Inc. (NEUE) Delisted | 10%+ Owner | — | $6.75 | — | $0 | 2 | 2024-10-03 |
| MBX | 10%+ Owner | 3,614,486 | $60.06 | $217.09M | $8.00M | 1 | 2024-09-17 |
| SVRA | 10%+ Owner | 24,471,264 | $5.33 | $130.43M | $1000.0K | 1 | 2023-07-19 |
| MIRM | 10%+ Owner | 30,135 | $112.23 | $3.38M | $6.75M | 2 | 2023-06-15 |
| Akouos, Inc. (AKUS) Delisted | 10%+ Owner | 0 | $13.29 | $0 | $10.00M | 2 | 2022-12-02 |
| GENOCEA BIOSCIENCES, INC. (GNCA) Delisted | 10%+ Owner | 0 | $0.00 | $0 | $21.03M | 4 | 2022-05-26 |
| TRVI | 10%+ Owner | 948,948 | $18.43 | $17.49M | $31.80M | 4 | 2022-04-13 |
| Metacrine, Inc. (MTCR) Delisted | 10%+ Owner | 2,563,257 | $0.49 | $1.27M | $9.51M | 2 | 2021-12-27 |
| GLUE | 10%+ Owner | 5,973,296 | $22.04 | $131.65M | $19.95M | 1 | 2021-06-30 |
| MRKR | 10%+ Owner | 1,071,428 | $1.18 | $1.26M | $10.00M | 1 | 2021-03-18 |
| Regulus Therapeutics Inc. (RGLS) Delisted | 10%+ Owner | 645,106 | $8.16 | $5.26M | $3.96M | 3 | 2020-12-07 |
Recent Filings · Page 5 of 5
42 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-05-09 | Regulus Therapeutics Inc. (RGLS) Delisted | Buy (P) | +1,136,704 | $1.23M | EDGAR |
| 2019-02-19 | GENOCEA BIOSCIENCES, INC. (GNCA) Delisted | Buy (P) | +9,948,269 | $4.69M | EDGAR |
Showing 41–42 of 42
Prev
Page 5 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.